Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT)
(Berlin: WTC) and CBDual Biotechnology Corp announced today that the
two companies have reached a comprehensive cross-licensing agreement.
This agreement covers intellectual property involving application of
technology and process patents to produce high quality pharmaceutical
grade cannabis materials. The patented technology facilitates the
production of cannabinoid formulations that may include Cannabidiol
(CBD) and Tetrahydrocannabinol (THC) that can be easily mixed into
fluids or medications providing increased stability of products and a
much quicker enhanced absorption rate of medications.
Dr. Greg Rubin, CEO of CBDual Biotechnology Corp. commented, “The
cannabis derived products market is growing rapidly in North America.
Market Research Future reports indicate that U.S., Canada, and Mexico
are dominant markets for cannabis products and these markets are
expected to grow at 33% per annum from 2016 to 2021. Growing awareness
about cannabis medicinal properties is also reflected in growing demand
for new CBD based products. The development of consumer and medical
products require the development of the best quality and utilization of
the most innovative technologies in order to achieve ultimate results.
This is only possible if we use the most advanced technological
processes and our agreement with CTi enables us to manufacture the best
quality CBD based oral care products by utilizing their advanced
Global Technology Manager of CTi, Roman Gordon, stated that,
“Intellectual property covered by this agreement between our companies
enhances the development of cannabis based products and helps us expand
into new consumer and medical markets. Cannabis based medicine is now
emerging and being revisited as a potential source of treatments for
conditions not addressed properly by synthetic substances,” concluded
CTi’s cross-licensing arrangement with CBDual Biotechnology Corp will
oversee the infusion of cannabinoids in CBD based oral healthcare
product line that includes mouthwash, toothpaste with cannabidiol and
other unique formulations. Management also sees the potential to attract
a number of potential licensees and distributors across multiple
markets, including the therapeutic foods, CBD water, dietary supplements
and pharmaceutical industries.
Founded in 2007, the company designs and manufactures
state-of-the-art, flow-through, devices and systems as well as develops
processing technologies for use in edible oil refining, renewable fuel
production, expeditious petroleum upgrading, algae oil extraction,
alcoholic beverage enhancement and water treatment. As an add-on to its
existing neutralization systems, the company’s patented Nano Reactor™
allows refiners to significantly reduce both processing costs and
environmental impact, while also increasing yield.
About CBDual Biotechnology Corp.
CBDual Biotechnology is a privately held, US based Biotechnology
company with a proprietary technology for enhanced oral delivery of
bioactive cannabinoids. This technology promotes good gums health and
overall dental health due to higher effectiveness of the delivery
methodology. Company was founded in 2016 and is headquarted in
California with its R&D capability in Israel and Ukraine.
CBDual Biotechnology is a pharmaceutical research and development
company, focused on the commercialization of cannabinoids (CBD) based
oral hygiene products and for the treatment of gum disease, bad breath,
pain and other disorders associated with oral health, including CBD
mouthwash, CBD toothpaste and other unique pharmaceutical products.
Company conducts medical research and clinical trials in their new
clinical research center in California. Company’s Medical Advisory Board
has experienced, Board certified doctors and specialists that oversee
and design clinical research and develop new products.
Forward Looking Statement
This release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
“may,” “should,” “potential,” “continue,” “expects,” “anticipates,”
“intends,” “plans,” “believes,” “estimates,” and similar expressions,
and include statements regarding the anticipated installation and the
timing of the installation, our intent to continue to focus on research
and development, marketing and sales of our unique technology, our
belief that our company is positioned for accelerated growth and the
expected efforts to be made to enhance our shareholder’s value. These
forward-looking statements are based largely on the Company’s
expectations and are subject to a number of risks and uncertainties,
certain of which are beyond the Company’s control. Actual results could
differ materially from these forward looking statements as a result of a
variety of factors including, among others, the state of the economy,
the competitive environment and our ability to perform the installation
as anticipated and other factors described in our most recent Form 10-K
and our other filings with the SEC, including subsequent periodic
reports on Forms 10-Q and 8-K. In light of these risks and uncertainties
there can be no assurances that the forward looking statements
contained in this press release will in fact transpire or prove to be
accurate. The information in this release is provided only as of the
date of this release, and we undertake no obligation to update any
forward-looking statements contained in this release on account of new
information, future events, or otherwise, except as required by law.
Cavitation Technologies, Inc.
Phone (818) 718-0905